PALO ALTO, Calif., June 4, 2024 /PRNewswire/ -- DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced an equity investment by the Merck Global Health Innovation Fund (GHIF), the corporate venture capital arm of Merck & Co., Inc, known as MSD outside the United States and Canada.

加利福尼亚州帕洛阿尔托，2024年6月4日/PRNewswire/--DELFI Diagnostics，Inc.是一家基于血液的无障碍检测的开发公司，提供了一种增强癌症检测的新方法，今天宣布由默克全球健康创新基金（GHIF）进行股权投资，该基金是默克公司（Merck＆Co.，Inc.）的企业风险投资部门，在美国和加拿大以外被称为MSD。

The capital will accelerate and expand DELFI's development and commercialization of its cancer detection solutions. DELFI's fragmentomics technology applies artificial intelligence (AI) to whole-genome sequencing data to compare an individual's cell-free DNA (cfDNA) patterns and characteristics against populations with and without cancer..

首都将加速并扩大DELFI癌症检测解决方案的开发和商业化。DELFI的fragmentomics技术将人工智能（AI）应用于全基因组测序数据，以比较个体的无细胞DNA（cfDNA）模式和特征与患有和不患有癌症的人群。。

The investment is expected to yield a range of innovative approaches to address the gaps in detection and monitoring treatment efficacy for millions of patients facing cancer now and in the years ahead.

预计这项投资将产生一系列创新方法，以解决目前和未来数年数百万癌症患者在检测和监测治疗效果方面的差距。

'We are thrilled to enter this strategic agreement with the Merck Global Health Innovation Fund,' said Susan Tousi, DELFI's Chief Executive Officer. 'This investment will help propel our fragmentomics and AI technologies, with the potential to make a meaningful population-scale difference in detecting cancer early with high precision at a disruptive price.'.

德尔菲首席执行官苏珊·图西（SusanTousi）说，我们很高兴能与默克全球健康创新基金（Merck Global Health Innovation Fund）达成这项战略协议这项投资将有助于推动我们的碎片组学和人工智能技术，有可能在以颠覆性价格高精度早期检测癌症方面产生有意义的人口规模差异。”。

'Early detection is key to improving outcomes for people with cancer,' said David M. Rubin, Ph.D., Managing Director at Merck Global Health Innovation Fund. 'We look forward to working with the DELFI leadership to build on the achievements to date and further expand lung cancer screening access.'

默克全球健康创新基金（Merck Global Health Innovation Fund）董事总经理大卫·M·鲁宾（DavidM.Rubin）博士说，早期发现是改善癌症患者预后的关键我们期待着与DELFI领导层合作，以迄今为止的成就为基础，进一步扩大肺癌筛查的机会。”

DELFI has commercialized the FirstLook Lung test, which evaluates patterns of DNA fragments in the blood that reveal the presence of lung cancer. In an independent validation, FirstLook Lung was shown to have 80% sensitivity in a screening population, including reliable detection of the earliest stages of the disease.

DELFI已经将FirstLook肺测试商业化，该测试评估血液中DNA片段的模式，揭示肺癌的存在。在一项独立验证中，FirstLook肺在筛查人群中显示出80%的敏感性，包括可靠地检测疾病的最早阶段。

The test also demonstrated a negative predictive value (NPV) of 99.8% – a measure of how unlikely low-dose CT scans will detect lung cancer if the FirstLook Lung test returns a 'Not Elevated' result. .

该测试还显示了99.8%的阴性预测值（NPV），这是一种衡量低剂量CT扫描在FirstLook肺部测试返回“未升高”结果时检测肺癌的可能性的指标。。

About DELFI DiagnosticsDELFI Diagnostics is developing next-generation, blood-based tests that are accurate, accessible and deliver a new way to help detect cancer. Employing advanced machine-learning methods to whole-genome sequencing data, the DELFI platform is built to address the highest-burden health challenges.

关于DELFI Diagnostics DELFI Diagnostics正在开发下一代基于血液的测试，这些测试准确，可访问，并提供了一种帮助检测癌症的新方法。DELFI平台采用先进的机器学习方法对全基因组测序数据进行处理，旨在解决负担最重的健康挑战。

We prioritize solutions that potentially save lives on a global scale, including for historically underserved populations. DELFI's platform relies on fragmentomics – the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments.

我们优先考虑可能在全球范围内拯救生命的解决方案，包括历史上服务不足的人群。DELFI的平台依赖于碎片组学，即发现癌细胞比正常细胞更混乱，当它们死亡时，会留下无细胞DNA（cfDNA）片段的模式和特征。

FirstLook Lung, for individuals eligible for lung cancer screening, is our first laboratory-developed screening test and can be part of routine blood work. FirstLook Lung uses millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early-stage disease, with a negative predictive value of 99.8 percent.

FirstLook Lung针对符合肺癌筛查条件的个体，是我们第一个实验室开发的筛查测试，可以作为常规血液工作的一部分。FirstLook Lung使用数百万个数据点可靠地识别可能通过低剂量CT检测到癌症的个体，包括早期疾病，阴性预测值为99.8%。

This test has not been cleared or approved by the FDA. To learn more about the FirstLook Lung test, visit www.delfidiagnostics.com or www.firstlooktest.com..

该测试尚未获得FDA的批准或批准。要了解有关FirstLook肺测试的更多信息，请访问www.delfidiagnostics.com或www.firstlooktest.com。。